Molecular mechanisms in obesity-associated metabolic disease by Olofsson, Louise
 
 
 
MOLECULAR MECHANISMS IN OBESITY-
ASSOCIATED METABOLIC DISEASE 
 
 
 
 
 
 
LOUISE OLOFSSON 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Institute of Medicine 
Department of Molecular and Clinical Medicine 
Sahlgrenska Academy 
Göteborg University 
 
2007 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ISBN 978-91-628-7180-2 
Printed by Intellecta Docusys AB 
Göteborg, Sweden 2007 
 
 
   
ABSTRACT 
Obesity is associated with increased morbidity and mortality. Subjects with obesity are at 
risk of developing several serious conditions such as type 2 diabetes, hypertension, 
coronary heart disease and stroke. This thesis aimed to identify genes that are implicated 
in the development of these obesity-associated metabolic diseases and to further increase 
our knowledge about these genes in relation to disease.  
 
Adipose tissue, especially intra-abdominal adipose tissue, is tightly linked to metabolic 
disease. Identification of genes predominantly expressed in adipocytes can give new 
insights into adipocyte function and may thereby provide important information about 
genes involved in the development of obesity-associated metabolic disease. The acute-
phase protein serum amyloid A (SAA) was unexpectedly found to be predominantly 
expressed in adipocytes during the nonacute-phase. Since SAA has been suggested to 
have multiple atherogenic effects, the production of SAA in adipose tissue may be a link 
between obesity and atherosclerosis. 
 
Potential susceptibility genes for obesity-associated metabolic disease were identified 
based on their altered expression in adipose tissue from obese individuals with the 
metabolic syndrome compared with controls that persisted even when the disease 
phenotype was temporarily improved by a very low calorie diet treatment. Using this 
approach, S100 calcium binding protein A1 (S100A1), Zn-alpha2-glycoprotein (ZAG), 
and CCAAT/enhancer binding protein alpha (C/EBPα) were identified as potential 
susceptibility genes. Subsequent genetic association study revealed a link between 
S100A1 and resting metabolic rate. A common ZAG genotype was associated with 
reduced ZAG gene expression, reduced serum levels of ZAG and low serum total 
cholesterol levels in humans. This genotype was also associated with coronary artery 
disease, which may be a result of decreased serum levels of adiponectin or HDL. 
Furthermore, data from studies in mice suggest that ZAG influences cholesterol 
synthesis. Thus, studies in both humans and ZAG-deficient mice showed a link between 
ZAG and cholesterol. Studies of the transcription factor C/EBPα showed that it is 
induced by insulin and in turn regulates multiple genes in the lipid and glucose 
metabolism including adiponectin, hexokinase 2, lipoprotein lipase, diacylglycerol O-
acyltransferase 1 and 2. 
 
In conclusion, SAA, S100A1, ZAG and C/EBPα were identified as potential 
susceptibility genes for obesity-associated metabolic disease using two different 
expression-based approaches. Our subsequent studies of these genes linked them to 
metabolic parameters known to influence or to be associated with metabolic disease e.g. 
resting metabolic rate, serum cholesterol levels and glucose and lipid metabolism. 
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VLCD very low calorie diet 
VLDL very low density lipoprotein 
WHO World Health Organization 
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ZAG Zn-alpha2-glycoprotein  
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BACKGROUND 
Obesity and associated metabolic disease 
Overweight and obesity are defined as excessive fat accumulation that may 
impair health. Body mass index [BMI; BMI=weight (kg)/height2 (m2)] is 
commonly used to classify overweight and obesity. Individuals are classified as 
overweight or obese if their BMI are ≥25 or ≥30 kg/m2, respectively. The 
International Obesity TaskForce has estimated that presently 1.1 billion adults 
worldwide are overweight including 312 million who are obese1 and that this 
number will continue to rise in the early 21st century. Subjects with obesity are at 
risk of developing one or more serious medical conditions including type 2 
diabetes, hypertension, coronary heart disease, stroke, as well as some types of 
cancers2,3. Obesity is thus associated with increased mortality4. 
 
Risk factors for cardiovascular disease 
Cardiovascular disease, including coronary artery disease and stroke, is rapidly 
increasing in prevalence in the wake of the obesity epidemic5. Several risk factors 
for cardiovascular disease have been identified6. These include: 
• Heredity - Studies have estimated that the heredity of cardiovascular 
disease is approximately 40-60%7. For more details regarding the 
genetics of this disease see below. 
• Age - Atherosclerosis begins at young age and increases in prevalence 
with age. Already at the age of 15, atherosclerotic lesions have formed8. 
However, according to the American Heart Association over 83% of the 
subjects dying from cardiovascular disease are 65 years or older. 
• Gender - In middle-age individuals, coronary heart disease is 2 to 5 
times more common in men than in women, which may partly be 
explained by sex differences in the major risk factors for coronary heart 
disease9.  
• Obesity/overweight - Obesity, especially visceral obesity, is tightly 
liked to metabolic disease. Adipose tissue is known to be an endocrine 
organ, secreting factors that affect other organs in the body. The 
importance of the adipose tissue in metabolic disease is discussed in 
more detail below. 
• Smoking - Smoking is a risk factor for myocardial infaction and 
stroke10,11. The risk of stroke decreased significantly two years after 
smoking cessation and returned to the level of nonsmokers after five 
years11. 
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• Blood lipids - Epidemiological studies have shown a positive correlation 
between serum total cholesterol and mortality in cardiovascular disease. 
However, serum total cholesterol is not the best predictor of 
cardiovascular disease, since it is the sum of the cholesterol in the 
atherogenic very low density lipoprotein (VLDL), intermediate density 
lipoprotein (IDL) and low density lipoprotein (LDL) but also the 
atheroprotective high density lipoprotein (HDL). In a meta-analysis 
including 58 trials, a LDL cholesterol reduction of 1.0 mmol/L reduced 
the risk of ischemic heart events by 11% in the first year of treatment, 
24% in the second year, 33% in years three to five, and by 36% 
thereafter12. Low HDL-C is also a strong and independent risk factor for 
coronary artery disease, commonly occurring in subjects with coronary 
artery disease13. In addition, the apolipoprotein B (apoB) to apoA-I ratio 
is positively related to fatal myocardial infarction14. Increased serum 
levels of triglycerides (TG) are also associated with increased coronary 
artery disease15.  
• Type 2 diabetes - It has been estimated that type 2 diabetes results in a 
2-4 fold increased risk of developing cardiovascular disease16. In 
addition, approximately 50-75% of the deaths of subjects with type 2 
diabetes are related to cardiovascular disease17.  
• Physical inactivity - Epidemiological studies suggest that physically 
active individuals have a 30-50% lower risk of developing type 2 
diabetes and a similar risk reduction for coronary artery disease 
compared to sedentary individuals. The reduced risk is observed after as 
little as 30 minutes moderate-intensity exercise per day18.  
• Blood pressure - Blood pressure is a strong and consistent predictor of 
development of cardiovascular disease19. 
• Low-grade inflammation - Modestly increased levels of acute-phase 
proteins, including serum amyloid A (SAA) and C-reactive protein 
(CRP), are independent risk factors for coronary artery disease in both 
men and women20-22. 
• Stress - Mental stress is considered a risk factor for cardiovascular 
disease23. 
 
Some of these risk factors including dyslipidemia, type 2 diabetes, elevated blood 
pressure, smoking, obesity and physical inactivity can be treated or avoided to 
prevent cardiovascular disease. 
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Definition of the metabolic syndrome 
It is well known that risk factors for coronary artery disease rarely occur alone. 
Instead, risk factors tend to cluster. This condition is referred to as the metabolic 
syndrome. Today, several different definitions of the metabolic syndrome exist. 
The World Health Organization (WHO) first published its definition in 199824. 
Subsequently, other definitions were proposed including the definition from the 
National Cholesterol Education Program (NCEP) Expert Panel25. In an attempt to 
reach a consensus definition, the International Diabetes Federation modified the 
criteria for the metabolic syndrome in 200526. For definitions, see Table 1. 
Alexander et al showed that metabolic syndrome as defined by NCEP is a 
predictor of prevalent coronary artery disease27. The NCEP-definition of 
metabolic syndrome was associated with a 2-fold increase in age-adjusted risk of 
fatal cardiovascular disease in men and non-fatal cardiovascular disease in 
women28. The definition by WHO resulted in slightly lower increase in risk. 
Metabolic syndrome defined by NCEP is also associated with increased 
mortality29. The prevalence of NCEP-defined metabolic syndrome is increasing 
and is now estimated to affect 21.8% of the adults in US30. The prevalence of the 
metabolic syndrome as defined by WHO was investigated in eight studies from 
seven different European countries. The overall prevalence of the metabolic 
syndrome was 14% in men and 4% in women under 40 years, 23% and 13% 
respectively for 40 to 55 years, and 41% and 26% respectively over 55 years of 
age31.  
 
Cardiovascular disease -Atherosclerosis 
Atherosclerosis is a progressive disease in which atherosclerotic lesions are 
formed in the vascular wall. These lesions may develop and cause coronary 
artery disease and stroke. The atherosclerotic lesions are thickenings of the 
innermost layer of the vascular wall and consist of lipids, fibrous connective 
tissue, cells, and debris32. The earliest stages of the atherosclerotic lesion are 
called fatty streaks. In this stage, the number of macrophages in the intima is 
increased and macrophages filled with lipids appear (foam cells)33. As the fatty 
streak develops, more macrophages are accumulated together with extracellular 
lipid pools and smooth muscle cells containing lipid droplets. A core of 
extracellular lipids is formed, as the atherosclerotic lesion evolves into an 
advanced one. In this stage, layers of fibrous connective tissues may also be 
formed. The advanced atherosclerotic lesions differ from one another. Some 
become calcified while others mainly consist of connective tissue32.  
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When the lesion grows, it decreases the diameter of the artery lumen and causes 
stenosis. The blood flow and oxygen delivery to the tissue supplied by the artery 
are then reduced. However, the main cause of infarction is not the progressive 
narrowing of the arteries, but disruption of the lesion surface, hematoma or 
hemorrhage and thrombosis. Some lesions are more prone than others to disrupt 
and cause thrombosis. Several factors may decrease the stability of the lesion 
including presence of inflammatory cells (macrophages and lymphocytes), 
release of toxic substances and proteolytic enzymes as well as shear stress. 
Plaques that disrupt are often lipid-rich34, and it has been found that serum 
cholesterol, in particular elevated ratio of total cholesterol to high density 
lipoprotein cholesterol (HDL-C), predispose patients to rupture of vulnerable 
plaques35.  
 
Adipose tissue distribution and metabolic disease 
Adipose tissue can be divided into intra-abdominal and subcutaneous adipose 
tissue. The intra-abdominal adipose tissue is also called visceral adipose tissue 
and is located inside the peritoneal cavity. The subcutaneous adipose tissue is 
located beneath the skin. In addition to visceral and subcutaneous adipose tissue, 
muscle has been shown to contain a relevant amount of lipids36,37. Several 
anthropometric measurements are currently used to describe regional obesity 
including circumferences of waist and hip, ratio of waist-hip circumferences 
(WHR) and sagittal diameter38. The visceral depot is more closely associated to 
cardiovascular disease and type 2 diabetes compared with subcutaneous adipose 
tissue39. This divergence may be a result of depot differences in location in 
relation to other organs, function and response to signals. Unlike subcutaneous 
fat, visceral fat drains directly into the portal vein, which transports the blood to 
the liver. It is therefore believed that the visceral depot can affect hepatic lipid 
and glucose metabolism to a greater extent compared to the subcutaneous 
depot39. Visceral fat has also been reported to be resistant to insulin suppression 
of lipolysis40,41 and the tissue is sensitive to β3-adrenergic stimulation of 
lipolysis42,43. The resulting non-esterified fatty acid (NEFA) flux to the liver may 
lead to altered liver metabolism including increased hepatic glucose production44. 
 
Storage of triglycerides in adipose tissue 
Most of the body’s energy is stored as triglycerides and glycogen. Adipose tissue 
is the main energy reservoir and stores mainly triglycerides. Triglycerides 
contain three fatty acid molecules esterified to one glycerol molecule. The 
synthesis of triglycerides has previously been extensively reviewed45. 
Triglycerides can be synthesized from glucose, which during glycolysis forms 
 11 
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glycerol-3-phosphate. Glycerol-3-phosphate is then further metabolised through a 
series of reactions, catalyzed by mitochondrial glycerol-3-phosphate 
acyltransferase (GPAM), glycerol-3-phosphate O-acyltransferase (GPAT3), 
phosphatidic acid phosphohydrolase (PAP2) and diacylglycerol O-
acyltransferase 1 and 2 (DGAT1 and 2), to form triglycerides. In addition, 
triglycerides can be formed from components of the plasma membrane i.e. 
phosphatidylinositol and phosphatidylcholine. This synthesis is catalyzed by 
phospholipase C and DGAT 1 and 2. The transcription factors sterol regulatory 
element-binding protein 1c (SREBP-1c), peroxisome proliferator-activated 
receptor gamma (PPARγ), and liver X receptor are important regulators of 
triglyceride synthesis. 
 
Lipolysis in adipose tissue 
The breakdown of triglycerides stored in the adipose tissue is known as lipolysis. 
In this reaction, triglycerides are hydrolyzed into free fatty acids and glycerol. 
This process is important during starvation to supply other organs with fuel and 
to provide the liver with substrates for the gluconeogenesis and lipoprotein 
synthesis46,47. It was recently discovered that during lipolysis the first ester bond 
in triglycerides is predominantly catalysed by adipose triglyceride lipase. The 
resulting diacylglycerols are mainly hydrolysed by hormone sensitive lipase 
(HSL) and the hydrolysis of monoacylglycerol is performed by monoglyceride 
lipase48. In addition to these lipases, several proteins known as PAT-proteins 
including perilipin, adipocyte differentiation-related protein, and tail interacting 
protein TIP-47 are important in lipolysis49. The mobilization of triglycerides is 
tightly regulated. The insulin-mediated inhibition and catecholamine-mediated 
stimulation of lipolysis are well characterized. The catecholamine stimulation is 
mediated by binding to the β3 adrenergic-receptor leading to phosphorylation of 
HSL and perilipin by protein kinase A. Phosphorylation of HSL activates this 
enzyme. In addition, phosphorylation of perilipin is essential for translocation of 
HSL to the surface of the lipid droplets49. In addition to insulin and 
catecholamines, other hormones and adipokines regulate lipolysis including 
growth hormone, glucocorticoids, atrial natriuretic peptide, leptin, resistin, TNF-
α, IL-6, and adiponectin48. However, the mechanisms involved in the regulation 
by these factors are unknown or not fully understood. 
 
Adipose tissue as an endocrine organ 
Adipose tissue secretes factors, so called adipokines, that affect other organs in 
the body (Figure 1). These include adipokines that effects energy regulation, 
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insulin sensitivity, lipid metabolism, and inflammation. Leptin and adiponectin 
are two of the most studied adipokines.  
 
Leptin was originally cloned in 1994 and lack of this hormone causes obesity in 
ob/ob-mice50. Leptin is secreted by the adipose tissue and regulates appetite and 
food intake by signalling to the central nervous system51,52. Serum leptin 
concentrations correlate with percent body fat and decrease during weight loss53. 
Leptin-deficiency in humans is rare and results in obesity, hyperinsulinemia, 
dyslipidemia and immune dysfunction54,55. These disturbances are improved by 
leptin-treatment55.  
 
Adiponectin is a 244 amino acid protein of approximately 28 kDa that occurs in 
the circulation as low molecular weight oligomeres and high molecular weight 
multimeres56. Adiponectin is secreted from adipose tissue and appears to have 
multiple beneficial and protective effects including anti-inflammatory, 
vasculoprotective and anti-diabetic effects56. Studies of adiponectin-deficient 
mice show that these mice have impaired insulin sensitivity57,58. In contrast to 
leptin, mRNA and serum levels of adiponectin decrease with increasing adipose 
tissue mass59,60. These adipokines illustrates the importance of adipose tissue as 
an endocrine organ. 
 
Insulin resistance and adipose tissue 
Insulin resistance is a condition where normal levels of insulin fail to evoke 
normal response in target tissues e.g. liver, skeletal muscle, and adipose tissue. 
Insulin stimulates glucose up-take in skeletal muscle and adipose tissue and 
suppresses the endogenous glucose production in the liver61. These effects result 
in decreased blood glucose concentration in response to insulin. In individuals 
with insulin resistance, the response to insulin is limited. To compensate for the 
loss of action, β-cells in pancreas secrete more insulin leading to 
hyperinsulinemia62. This compensatory hypersecretion of insulin is a result of 
both expansion of β-cell mass and alterations in β-cell metabolism62. In subjects 
with insulin resistance, hyperinsulinemia can keep the glucose levels within a 
normal range for some time. However, glucose levels are mildly increased in 
these subjects, which may be toxic to the β-cells and cause β-cells 
dysfunction63,64 and cell death. Some studies have found a reduced number of β-
cells in individuals with type 2 diabetes65. 
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Inflammation 
TNFα 
IL-1β 
IL-6 
IL-8 
IL-10 
TGFβ 
MCP-1 
Acute phase 
proteins 
PAI-1 
Haptoglobin 
SAA 
Lipid metabolism
CETP 
LPL 
ZAG 
Appetite/Energy 
regulation 
Leptin 
IL-6 Insulin sensitivity/ Glucose 
homeostatis 
Adiponectin 
Resistin 
Visfatin 
ASP 
RBP4 
TNFα  
Figure 1. Adipose tissue is an endocrine organ secreting adipokines that affect energy 
regulation, insulin sensitivity, lipid metabolism, and inflammation. TNFα, tumor necrosis factor 
α; IL, interleukin; TGFβ, transforming growth factor β; MCP-1, monocyte chemotactic protein 1; 
CETP, cholesteryl ester transfer protein; LPL, lipoprotein lipase; ZAG, Zn-alpha2-glycoprotein; 
C3, complement component 3; RBP4, retinol-binding protein 4; PAI-1, plasminogen activator 
inhibitor 1; SAA, serum amyloid A. 
 
64Insulin resistance is strongly associated with obesity  and studies indicate 
several mechanisms by which adipose tissue is implicated in the pathology. 
Hormones, cytokines and NEFA, secreted from the adipose tissue, can affect 
insulin signalling. Both obesity and type 2 diabetes are associated with increased 
serum levels of NEFA66,67. The release of NEFA is important in modulating 
insulin sensitivity68. It inhibits both insulin-stimulated glucose up-take in skeletal 
muscle and stimulates gluconeogenesis in the liver. Furthermore, NEFA may be 
harmful for β-cells and thus contribute to its abnormal function during 
development of type 2 diabetes69. In addition to the effects mediated by NEFA, 
adipose tissue secretes hormones, including adiponectin, retinol-binding protein 
4, visfatin and resistin, that can affect insulin sensitivity. The important role of 
adipose tissue in the pathology of insulin resistance is also demonstrated by the 
fact that the class of anti-diabetic drugs called Thiazolidinediones (TZD) act via 
the transcription factor peroxisome proliferator-activated receptor gamma 
(PPARγ), mainly expressed in adipose tissue70. TZD decrease insulin resistance 
partly by modulating the expression of adipokines including adiponectin, retinol 
binding protein-4 and leptin71,72. In addition, DGAT1 mRNA are positively 
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correlated with insulin sensitivity and increase in response to TZD. These data 
suggest that lipid storage in adipose tissue can prevent peripheral lipotoxicity73. 
 
Lipoproteins –synthesis and metabolism of apoB-
containing lipoproteins 
Lipids are transported in the blood in complex with apolipoproteins forming so-
called lipoprotein particles. These particles have a neutral core consisting of 
cholesterol esters and TG. The surface of the particles is a monolayer of the 
partly hydrophilic molecules; phospholipids and free cholesterol. The 
apolipoproteins are embedded in this surface layer. The lipoproteins are 
classified based on their density and include chylomicrons, VLDL, IDL, LDL, 
and HDL. Multiple apolipoproteins have been discovered and are constituents of 
the lipoproteins74. ApoB100 and apoB48 are encoded by the same gene. Post-
transcriptional deamination of cytidine to a uridine in apoB48 results in a stop-
codon instead of the glutamine codon present in apoB100. Hence, apoB48 is 
identical to the N-terminal part of the apoB100. ApoB100 is mainly synthesised 
in human liver, where VLDL is assembled and secreted into the bloodstream. 
The production rate of VLDL is primarily controlled by the availability of neutral 
lipids i.e. triglycerides and cholesteryl esters47. The apoB100 production is also 
important. However, apoB is produced in excess and will therefore not regulate 
the VLDL production under most physiological conditions. In contrast to 
apoB100, apoB48 is mainly produced in the intestine and is a constituent of 
chylomicrons. VLDL and chylomicrons are metabolized by lipoprotein lipase 
(LPL), hepatic lipase (HL), and cholesteryl ester transfer protein (CETP) in the 
circulation. LPL and HL hydrolyze triglycerides and phospholipids present in 
circulating plasma lipoproteins75,76. CETP promotes redistribution of lipids 
among lipoproteins with a net transfer of cholesteryl esters from HDL to 
triglyceride-rich lipoproteins (VLDL and chylomicrons), and LDL and of 
triglycerides from triglyceride-rich lipoproteins to LDL and HDL77. During the 
processing of VLDL and chylomicrons, the metabolites IDL, LDL and 
chylomicron remnants are formed (Figure 2). Removal of these remnants from 
the bloodstream occurs mostly by uptake mediated by the LDL-receptor, the 
LDL receptor-related protein and the macrophage scavenger receptor (MSR1)78-
82. 
 
Reverse cholesterol transport 
HDL is important for reverse cholesterol transport i.e. removal of cholesterol 
from peripheral tissue and transporting it to the liver (Figure 3). The major 
apolipoprotein of HDL is apoA-I74. Both the liver and the intestine are able to 
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synthesize and secrete apoA-I. Subsequent lipidation of apoA-I is mediated by 
the lipid transporting protein ATP-binding cassette transporter A1 (ABCA1), 
which promotes efflux of unesterified cholesterol and phospholipids. Studies of 
mice specifically lacking hepatic or intestinal ABCA1 together with liver-
specific partial gene knockdown of ABCA1 have shown that ABCA1 in liver and 
intestine are important in this lipidation process83-85. Although liver and intestine 
ABCA1 may be the most critical for lipidating newly synthesized lipid-free 
apoA-I, substantial cholesterol efflux to HDL occurs from other tissues. 
 
 
LPL
LPL 
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apo B100 
Adipose 
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LDL 
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HDL 
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HDL 
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Figure 2. Lipoprotein metabolism. Chylomicrons and very low density lipoproteins (VLDL) are 
secreted from the intestine and liver, respectively. These lipoproteins are metabolized by 
lipoprotein lipase (LPL), hepatic lipase (HL), and cholesteryl ester transfer protein (CETP) in the 
circulation, forming the metabolites chylomicron remnants, intermediate density lipoproteins (IDL) 
and low density lipoproteins (LDL). These metabolites are removed from the bloodstream by 
receptor-mediated uptake. ApoA-I is secreted from the intestine and liver, and lipidated in the 
blood to form mature high density lipoproteins (HDL). Apo, apolipoprotein. 
 
In addition to ABCA1, ABCG1 also mediates cholesterol efflux from cells. 
However, ABCG1 only promotes cholesterol efflux from cells to HDL and other 
lipoprotein particles and not to lipid-free apoA-I86. Studies in mice suggest that 
approximately 90 mg cholesterol per kg body weight is effluxed from peripheral 
tissues every 24h87. In the circulation, HDL is modified by multiple proteins 
including lecithin:cholesterol acyltransferase (LCAT), HL, endothelial lipase 
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(EL), phospholipid transfer protein (PLTP), and CETP. LCAT converts 
cholesterol and phosphatidylcholines (lecithins) to cholesteryl esters and 
lysophosphatidylcholines on the surface of HDL88. PLTP is also important in 
remodeling of the HDL particle and has for example been found to transfer 
surface lipids from triglyceride-rich lipoproteins to HDL89. Scavenger receptor 
type B class I binds HDL with high affinity and mediates selective uptake of 
cholesterol82. 
 
Bile 
Lipid-
poor 
apoA1 
Peripheral 
tissue 
VLDL/IDL/
LDL 
Intestine 
Macrophage 
Mature 
HDL 
Liver 
apo A1 
CETP 
PLTP 
LCAT 
HL EL 
apo B100 
 
 
Figure 3. Reverse cholesterol transport. ApoA-I is secreted from the intestine and liver, and is 
lipidated in the blood to form mature high density lipoproteins (HDL). Multiple proteins are 
important for HDL remodeling in the circulation including phospholipid transfer protein (PLTP), 
cholesteryl ester transfer protein (CETP), hepatic lipase (HL), endothelial lipase (EL), and 
lecithin:cholesterol acyltransferase (LCAT). VLDL, very low density lipoprotein; IDL, 
intermediate density lipoprotein; LDL, low density lipoprotein; HDL, high density lipoprotein; apo, 
apolipoprotein. 
 
Regulation of cholesterol 
Approximately 1 g cholesterol is synthesized every 24 hours in humans through 
the reactions shown in Figure 4. When sterol synthesis was investigated in vivo 
in 18 tissues from squirrel, monkey, guinea pig, rabbit, hamster and rat it was 
found that when expressed as a percentage of total body synthesis, the liver of the 
rat produced 51%, while this figure was much lower in the monkey (40%), 
hamster (27%), rabbit (18%), and guinea pig (16%)90. It was concluded that most 
sterol utilized by extrahepatic tissues is largely synthesized locally within those 
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tissues. In addition to synthesis, cholesterol can also be supplied by the food. The 
typical diet in Western countries contains 200-600 mg cholesterol per day91. In 
the intestine, cholesterol absorption values range widely from approximately 30-
80%92. Thus, cholesterol production constitutes the main source of cholesterol. 
To regulate the cholesterol content in the body, excessive cholesterol is excreted 
with the bile into the intestinal lumen, where it is partly re-absorbed and partly 
excreted with faeces. The internal cholesterol synthesis is regulated by the 
SREBPs, which belong to the basic helix-loop-helix-leucine zipper family of 
transcription factors. In the liver, cholesterol and fatty acid synthesis are 
regulated by three SREBPs; SREBP-1a, 1c and 293. SREBP-1a and c are encoded 
by the same gene and differ in the start site of transcription leading to two 
different exon 1. SREBP is produced as an inactive form, which needs 
proteolytic activation before it can activate transcription of target genes. This 
proteolytic activation involves the sterol sensing protein SREBP cleavage–
activating protein (SCAP). SCAP escorts SREBP from the endoplasmatic 
reticulum (ER), where it is translated, to the Golgi apparatus. In Golgi, SREBP is 
cleaved with the Site-1 and -2 proteases and the active N-terminal part of the 
protein is released from the membrane-bound part. The active N-terminal part of 
SREBP is then transported into the nucleus where it activates transcription 
through binding to sterol response elements in promoters and enhancer regions of 
target genes.  
 
The different forms of SREBP have been found to preferentially activate 
different target genes. SREBP-1c for example preferentially activates enzymes in 
the fatty acid synthesis. SREBP-2 preferentially activates enzymes in the 
cholesterol synthesis. In contrast, SREBP-1a is a potent activator of all SREBPs 
target genes. In liver, SREBP-1c and 2 are more abundant compared to SREBP-
1a. When the cholesterol content in the liver is high, insulin induced gene 1 
(Insig1) binds SCAP, resulting in an inhibition of the escort of SREBP to the 
Golgi apparatus by SCAP. Consequently, SREBP is not proteolytically activated 
by Site-1 and 2 proteases and therefore does not activate transcription of genes 
involved in the cholesterol synthesis. 3-hydroxy-3-methylglutaryl-coenzyme A 
reductase (HMG-CoA reductase), the rate-limiting enzyme in the cholesterol 
synthesis (Figure 4), is one of the genes regulated by the SREBP. 
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Figure 4. Cholesterol synthesis. Enzymes and products involved in the cholesterol synthesis are 
shown. HMG-CoA reductase is the rate-limiting step in the cholesterol synthesis. 
 
Genetics of complex disease 
Complex diseases are characterized by a complex etiology and are caused by an 
interaction between multiple genes and environmental factors. Identification of 
susceptibility genes for complex diseases is difficult due to the presence of: 
• Incomplete penetrance - A gene with incomplete penetrance will not 
always result in the phenotype with which it has been associated.  
• Phenocopies – Phenocopies are individuals with the phenotype 
investigated, caused by environmentally factors (nonhereditary 
variation).  
• Locus heterogeneity - If mutations or polymorphisms at a number of 
different loci result in the same phenotype. 
• Epistasis – Genotypes at two or more unlinked loci can interact e.g. 
when one gene affects the expression of another gene. 
• Pleiotropy - A locus or loci may predispose to more than one phenotype. 
• Effects of environmental factors  
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To identify susceptibility genes for complex disease two approaches have been 
used; the candidate gene and the phenotype driven. In the candidate gene 
approach, genetic variations in genes with known important functions are 
investigated. In the phenotype-based approach, genome-wide scans and 
association studies are used to search for new genes. 
 
Most forms of atherosclerosis, hypertension, dyslipidemia and type 2 diabetes are 
complex diseases. However, there are monogenic disorders that confer 
susceptibility to these diseases including familial hypercholesterolemia caused by 
mutations in the gene for the LDL-receptor, resulting in the inability to mediate 
binding, uptake and degradation of LDL94 and thereby confer risk of developing 
atherosclerosis. In addition, a mutation in apolipoprotein B also causes 
hypercholesterolemia through diminished LDL-uptake95. Environmental factors 
e.g. smoking, diet and exercise affect the outcome in individuals with these 
mutations. In addition, numerous genes that confer susceptibility to the complex 
form of cardiovascular disease have been identified including apoE, 
paraoxonase-1, and 5-lipoxygenase activating protein7,96,97. 
 
Quantitative trait loci (QTL) analysis has been used in humans and mice to 
identify new genes that regulate blood lipids. These analyses have resulted in 
identification of multiple QTLs controlling HDL-cholesterol, VLDL/LDL-
cholesterol and plasma triglycerides98,99. Several of the QTLs present in humans 
are also present in the homologous regions in mice, suggesting that the same 
genes are important in humans and mice. However, the complexity of the traits 
complicates the identification of susceptibility genes100. The best results have 
been achieved using inbred mice, in which the origin of the parental alleles are 
known and all animals have the same genetic background. In these studies, 
environmental factors can be controlled. Nevertheless, several common 
polymorphisms have been found to be associated with dyslipidemia. For 
example, polymorphisms in apolipoprotein E could explain as much as 8% of the 
variation in LDL-cholesterol concentrations101.  
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AIMS 
 
The overall aim of this thesis was to identify susceptibility genes important in the 
development of obesity-associated metabolic disease. Strategies to achieve this 
aim have been developed and applied in the different articles and manuscripts 
included in this thesis. The specific aims were: 
 
To identify a suitable reference gene for gene expression studies in human 
adipose tissue. (Paper I) 
 
To identify genes predominantly expressed in omental adipocytes. (Paper II) 
 
To identify genes with altered expression in subcutaneous adipose tissue from 
obese subjects with the metabolic syndrome compared with obese controls and 
link them to metabolic dysfunction. (Paper III-V) 
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METHODOLOGICAL CONSIDERATIONS 
Subjects 
This thesis included participants from the Very Low Calorie Diet 1 (VLCD-1) 
study, VLCD-2 study, Quebec Family Study, Swedish Obese Subjects (SOS) 
Reference Study, Intergene, Stockholm Coronary Atherosclerosis Risk Factor 
(SCARF), and Dallas Heart Study.  
 
VLCD-1 study 
102In the VLCD-1 study, subjects were originally included in the SOS study . A 
subgroup were recruited from the SOS study to evaluate the weight loss 
maintenance after very low calorie diet (VLCD), and diet and behavioural 
support103,104. From this subgroup, 14 obese subjects with the metabolic 
syndrome according to slightly modified WHO criteria24 and age-, sex-, and 
BMI-matched controls were selected for the gene expression analysis with DNA 
microarray in Paper I, III and IV. In Paper III-IV, genes with altered expression 
in subcutaneous adipose tissue from obese subjects with the metabolic syndrome 
compared with obese controls were identified. Table 2 shows extensive patient 
characteristics for the subjects included in this analysis. Biopsies and blood 
samples for this study were collected before (week 0), after 8 weeks (week 8) and 
2 weeks after completed 16-weeks VLCD (week 18). All of the subjects with the 
metabolic syndrome but none of the controls had type 2 diabetes. In addition to 
type 2 diabetes, the subjects with the metabolic syndrome also had elevated 
blood pressure and/or dyslipidemia as defined by WHO (Table 1). We did not 
have measurements for microalbuminuria and could therefore not include this 
parameter in the classification.  
 
VLCD-2 study 
In total, 40 subjects (34 men and 6 women) were recruited among patients treated 
at the Department of Body Composition and Metabolism, Sahlgrenska University 
Hospital and from advertisements in the local press. The criteria for inclusion 
were set to BMI ≥ 30 and age 25-60. Subjects were divided into two groups; 
individuals with the metabolic syndrome according to slightly modified WHO 
criteria24 and age-, sex-, and BMI-matched controls. Exclusion criteria were: 
medication (except antihypertensive therapy in the group with metabolic 
syndrome), pregnancy, breast feeding, type 1-diabetes mellitus, serious 
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Table 2. Characteristics of subjects from the VLCD-1 study used for expression analysis with 
DNA microarray.  
Subjects with the metabolic 
syndrome  Controls 
Characteristic Week 0 Week 8 Week 18 Week 0 Week 8 Week 18 
n (men/women) 14 (5/9)   14 (5/9)   
Age (years) 47.0±10.1   46.7±9.4   
BMI (kg/m2) 40.5±9.1 35.9±8.3 34.7±8.7 40.0±8.9 35.4±8.7 33.2±9.9 
WHR 1.0±0.1   1.0±0.1   
Sagittal diameter (cm) 29.4±4.7   29.0±3.7   
SBP (mmHg) 159±29 143±21 150±23 130±15 120±16 131±16 
DBP (mmHg) 92±20 85±14 85±12 86±11 76±9 77±9 
b-Glucose (mmol/L) 9.6±2.3 7.4±2.9 7.6±2.5 4.3±0.6 4.3±0.7 4.4±0.9 
Insulin (pmol/L) 26.6±15.6 14.9±6.6 16.1±9.7 14.4±9.4 11.3±8.3 11.8±10.6 
Cholesterol (mmol/L) 5.7±0.7 5.3±1.1 5.5±0.9 6.0±2.1 4.8±1.0 5.3±1.2 
HDL-C (mmol/L) 1.1±0.4 1.1±0.4 1.2±0.3 1.3±0.5 1.1±0.3 1.3±0.3 
TG (mmol/L) 2.5±1.3 1.9±1.1 2.1±1.1 1.8±1.0 1.3±0.5 1.3±0.4 
Obese subjects with the metabolic syndrome and controls matched for BMI, age and sex were 
treated with a very low calorie diet for 16 weeks followed by 2 weeks of gradual reintroduction of 
their ordinary diet. The metabolic syndrome was diagnosed according to slightly modified WHO 
criteria24. BMI, body mass index; HDL-C, high density lipoprotein cholesterol; TG, triglyceride. 
 
psychiatric disorder, established coronary heart disease, malignant arrhythmias, 
participation in any other ongoing weight reduction study, eating disorder, 
history of bariatric surgery or cancer treatment, drug abuse, insufficient 
compliance, other significant somatic disease, smoking or unwillingness to 
participate. The subjects with the metabolic syndrome had diabetes, impaired 
glucose tolerance, or impaired fasting glucose according to WHO24 and at least 
one of the following risk factors: (i) elevated arterial (systolic/diastolic) pressure 
≥ 140/90 mm Hg (either value) or use of blood pressure medication; (ii) raised 
triglycerides (≥ 1.7 mmol/L) and/or low HDL cholesterol (<0.9 mmol/L). 
Subjects were treated with VLCD during 16 weeks followed by two weeks of 
gradual reintroduction of the ordinary diet. During this study period biopsies and 
blood samples were collected at week 0, 8, 16 and 18. At these time points, 
anthropometric measurements and computer tomography were also performed. In 
a small subgroup of the patients, sampling and measurements were also 
performed at three additional time points; day 3, and week 2 and 4. Data, from 
subjects included in the VLCD-2 study, at week 0, 8, 16, and 18 were used in 
Paper II, IV and V. Table 3 shows extensive patient characteristics.  
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Quebec Family Study  
Subjects from the Quebec Family Study (QFS) were included in Paper III. In this 
study, resting metabolic rate was measured by indirect calorimetry in a 
ventilated-hood system and adjusted for age, sex, stature, and body composition 
(fat mass and fat free mass). For these adjustments, body density was measured 
by hydrodensitometry i.e. underwater weighing and total fat mass was derived 
from the equation of Siri105,106: % body fat = [(4.95/body density)-4.5]*100. Fat-
free mass was obtained by subtracting fat mass from body mass. In the Quebec 
Family Study (QFS), evidence for linkage to resting metabolic rate (RMR) was 
observed on chromosome 1q21.1 – q21.2107. Only 56 of the total 119 families 
were informative and contributed to this QTL in the QFS. Table 4 shows 
characteristics for the subjects included in QFS and used in the analysis in Paper 
III.  
 
Table 4. Patient characteristics for subjects in the QFS.  
Characteristics All QFS subjects Informative Non-informative 
N (men/women) 721 (327/394) 199 (85/114) 522 (242/280) 
Age (years) 38.6 ± 14.8 38.7 ± 15.7 38.2 ± 14.5 
BMI (kg/m2) 26.9 ± 7.0 27.6 ± 7.7 26.6 ± 6.7 
RMR (kJ/min) 1.1 ± 0.2 1.1 ± 0.3 1.1 ± 0.2 
Fat mass (kg) 21.9 ±14.0 23.5 ± 15.6 21.3 ± 13.2 
Fat free mass (kg)  52.4 ± 11.1 52.8 ± 12 52.4 ± 10.6 
WHR 0.84 ±0.10 0.85 ± 0.10 0.84 ±0.10 
SBP (mmHg) 114 ±12 113 ± 12 114 ± 13 
DBP (mmHg) 71 ± 12 70 ± 13 71 ± 11 
mmol/L) 4.9 ±1.1 4.9 ± 1.0 4.9 ± 1.1 Cholesterol (
HDL-C (mmol/L) 1.2 ± 0.3 1.2 ± 0.3 1.2 ± 0.3 
mmol/L) 3.0 ± 0.9 3.1 ± 0.8 3.0 ± 0.9 LDL-C (
TG (mmol/L) 1.5 ± 1.5 1.6 ± 0.8 1.5 ±1.6 
Glucose (mmol/L) 5.0 ± 0.9 5.0 ± 0.8 5.0 ± 1.0 
Insulin (pmol/L) 72.0 ± 60.8 77.3 ± 72.7 70.2 ±56.1 
Informative subjects contributed to the suggestive linkage to RMR on chromosome 1q21. BMI, 
body mass index; RMR, resting metabolic rate; HDL-C, high density lipoprotein cholesterol; LDL-
C, low density lipoprotein cholesterol; TG, triglyceride. 
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Intergene  
The Intergene study was designed to investigate which candidate genes that 
could explain the hereditary part of CAD in the population from the west part of 
Sweden. This study was also designed to investigate the interaction between 
susceptibility genes for CAD and external factors such as life style and 
environment as well as understanding the function of the candidate genes in the 
pathogenesis. The study is a combined control and cohort study of two thousand 
consecutive patients with coronary artery disease from hospitals situated in the 
western part of Sweden. The control group was selected from relatives of the 
patients and approximately 10.000 healthy individuals randomly selected from 
the population. Subjects were between 25 and 75 years old and lived in the 
western part of Sweden at the time of recruitment. Sampling took place between 
2001 and 2004. More information regarding the Intergene-study is available on 
http://www.sahlgrenska.gu.se/intergene/eng/index.jsp. Table 5 shows the 
characteristics of cases and controls included in Paper IV. 
 
Table 5. Characteristics for subjects in the Intergene-study 
Intergene  
Case Healthy subjects Characteristic 
n (men/women) 411 (296/115) 411 (296/115) 
Age (years) 61.2 ± 8.5 61.3 ± 8.5 
WHR 0.95 ±0.07 0.91 ± 0.08 
BMI (kg/m2) 27.5 ± 3.9 26.6 ± 3.5 
SBP (mmHg) 133 ± 21 142 ± 22 
DBP (mmHg) 82 ± 11 85 ± 10 
mmol/L) 5.6 ± 1.1 5.3 ± 0.9 Glucose (
Cholesterol (mmol/L) 4.6 ± 1.0 5.7 ± 1.0 
HDL-C (mmol/L) 1.3 ± 0.4 1.5 ± 0.4 
LDL-C (mmol/L) 2.6 ± 0.9 3.6 ± 0.9 
TG (mmol/L) 1.6 ± 1.1 1.5 ± 0.8 
Characteristics for subjects without diabetes in the Intergene divided into CAD-cases and healthy 
subjects and used in Paper IV to study the possible association between polymorphisms in the 
ZAG-gene and CAD. 
 
Expression analysis with DNA microarray 
Sequencing of the human genome108,109 has enabled development of methods for 
genome-wide analysis. Analysis of expression and polymorphisms using DNA 
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microarray are examples of such methods. These methods allow rapid genome-
wide analysis using an unbiased exploration strategy.  
 
Affymetrix GeneChip microarrays consist of small DNA fragments (probes), 
chemically synthesized at specific locations on a coated quartz surface. The 
probes are designed to determine whether or not the complementary sequence of 
RNA or DNA is present in the sample. They usually consist of 25 nucleotides 
and have high specificity for the target sequence. Normally 22 probes for each 
target transcript are used for gene expression measurements. For each probe on 
the array that perfectly matches its target sequence, one paired “mismatch” probe 
is present. This mismatch probe contains a single mismatch located directly in 
the middle of the 25-base probe sequence. The mismatch probe is used as a 
control for non-specific binding to the perfectly matched probe. For gene 
expression analysis, RNA is extracted from the samples, amplified, labelled, and 
hybridized to the array. The amount of a specific transcript is then measured.  
 
Different microarrays have been used to analyze gene expression in this thesis 
including HuGeneFL, HG-U95A, and HG-U133A. HuGeneFL was released in 
1998 and enabled the relative monitoring of mRNA transcripts of approximately 
5600 full-length genes. Since then HG-U95A and HG-U133set have been 
released, enabling monitoring of mRNA transcripts of 10,000 and 38,500 full-
length genes, respectively. This illustrates the rapid development of this 
technique. 
 
Expression analysis with real-time PCR 
To investigate mRNA levels using real-time PCR, mRNA is isolated and reverse 
transcribed into cDNA. The resulting cDNA is then used as template in the 
quantitative real-time PCR (TaqMan). For the gene of interest, a probe and 
primer set is designed. The forward and reverse primers are preferable designed 
to span an exon-exon boundary to allow amplification of cDNA but not genomic 
DNA. The probe is designed to be complementary to part of the sequence 
between the primers. The TaqMan-probes consist of an oligonucleotide 
containing a reporter dye (i.e. FAM™ or VIC®) at the 5′ end, and a 
nonfluorescent quencher dye at the 3′ end. During the exponential phase of the 
PCR amplification, the probe breaks down and the fluorescence increases due to 
increased distance between reporter dye and quencher, allowing determination of 
the number of copies of the target transcript in the starting mRNA. The 
Threshold Cycle (Ct), reflecting the PCR cycle number at which the fluorescence 
reaches a fixed threshold, is used to compare the number of copies of the target 
transcript in the different samples. Endogenous reference genes are commonly 
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used in quantitative real-time PCR analysis to adjust for sample variation such as 
different amount of starting RNA and different efficiency of cDNA synthesis. 
 
Genetic association studies 
Genetic association studies are commonly used to study the correlation between a 
genetic variant and a phenotype, usually the presence or absence of a disease or a 
quantitative disease-associated trait e.g. serum cholesterol levels. In the studies 
presented in this thesis, we have analyzed single nucleotide polymorphisms 
(SNPs). In SNPs, a particular base varies between two or more different 
nucleotides. However, SNPs are not the only genetic variant used in association 
studies. So-called tandem repeats or microsatellites, consisting of repeated DNA-
sequence built up by di-, tri- or tetranucleotide repeats, are also used. The DNA 
sequence variation is said to be polymorphic if the most common variant is 
present in less than 99% of the population.  
 
Several methods are available for genotyping SNPs including allele 
discrimination using flourophore-based PCR (TaqMan) and minisequencing 
(SNaPshot). There are advantages and drawbacks with both methods. TaqMan is 
a rapid genotyping method generating high-confidence results using as little as 2-
10 ng DNA. However, this method is not suitable when the genotyped SNP is 
located close to another SNP. Primer and probe design may also be difficult 
depending on the DNA-sequence surrounding the SNP. Primers for the more 
time- and DNA-consuming method, minisequencing, can often be more easily 
designed. Several SNPs may also be genotyped simultaneously using a multiplex 
minisequencing protocol, which can make this method more time-effective.  
 
Allelic imbalance 
Identification of genetic variants that affect gene regulation is expected to have 
an important role in the molecular characterization of complex traits110. Several 
different approaches have been applied to identify polymorphisms associated 
with gene expression. Analysis of transcriptional activity in an allelic-specific 
quantitative real-time PCR is a relatively easy way to study association between 
SNPs and gene expression. However, this approach requires that the mRNA 
contains at least one SNP. A drawback with this method is that it does not 
directly identify the cis-acting polymorphism or mechanism that is responsible 
for the variation in gene expression.  
We developed a real-time PCR-based assay to determine the relative expression 
of the two alleles of a SNP in the coding region of Zn-alpha2-glycoprotein 
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(ZAG). When individuals are heterozygous for an exonic polymorphism, it is 
possible to detect the relative abundance of allelic transcripts (Figure 5). 
 
T AAAA 
T AAAA C 
AAAA C 
T AAAA T 
T AAAA 
T AAAA 
C AAAA 
Cells from heterozygous 
individuals 
RNA isolation 
Quantification of allelic transcripts  
Expected ratio if 
equally expressed 
 
 
Figure 5. Strategy for studying the relative expression of the C and T alleles of the SNP 
rs4215, located in the coding region of the Zn-alpha2-glycoprotein gene. RNA was isolated 
from heterozygous individuals and the number of transcripts containing the C and T-alleles were 
determined using a real-time PCR assay. Genomic DNA and a cDNA standard, containing equal 
amount of the C and T-transcripts, were used as standard. 
 
Genetically modified mice 
Mice have during the last century become the most widely used animal model for 
studies of human complex disease. Certain mouse strains develop, in similarity to 
humans, complex diseases including cancer, obesity and type 2 diabetes. 
Furthermore, several other conditions that are not spontaneously developed in 
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mice can be induced by modifications of the mice genome and/or environment. 
There are additional reasons for choosing mice as animal model including the 
tools available for studying mice, the price, the short generation time, the size of 
the animal and the large number of animals per litter. Genetically modified mice 
that overexpress or lack one or more genes make it possible to study the gene 
function and possible implication in disease development. Techniques and 
knowledge now allow genetic modifications to be tissue-specific and to be 
induced at a chosen time point. We used mice with ZAG-deficiency to study the 
function of ZAG in cholesterol metabolism (Paper IV). The ZAG-deficient mice 
were crossed with human apoB100 transgenic mice to obtain mice with a 
lipoprotein profile that resembles the human profile111. The ZAG-deficiency was 
confirmed using RT-PCR on liver and Western blot analysis of serum. Further 
studies of the mice included techniques such as enzyme-linked immunosorbent 
assay (ELISA), DNA microarray, determination of liver cholesterol content, and 
serum cholesterol profiles.  
 
Adenovirus 
There are different ways to transfer genes into cells including transduction, 
transfection, direct gene transfer, and bacterial gene transfer. In this thesis, we 
used transduction i.e. virus-mediated gene transfer to study the effects of 
overexpression of C/EBPα in 3T3-L1 cells (Paper V).  
 
Members of the adenovirus family infect a great variety of post-mitotic cells 
through a receptor-mediated process. After infection, adenovirus delivers their 
genome to the nucleus and the viral genes are then transcribed, leading to 
replication of the genome112. For studies using virus-mediated gene transfer, parts 
of the viral genome have been removed in order to make the adenovirus less 
toxic for the cells. The removal of these genes inhibits the amplification of the 
virus. To amplify the virus before use, Ad-293 cells that contain the “missing 
genes” are used. 
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RESULTS AND DISCUSSION 
Evaluation of reference genes for studies of gene 
expression in human adipose tissue 
Reference genes are commonly used in quantitative real-time PCR analysis to 
adjust for sample variation such as different amount of starting RNA and 
different efficiency of cDNA synthesis. Other approaches have also been used to 
adjust for sample variations. For example, gene expression has been related to 
total RNA or cell count113. However, these approaches lack control of the cDNA 
synthesis step, and cell counts can only be applied in studies performed on cells 
and not tissues. Other strategies, such as spiking exogenous in vitro synthesized 
RNA114,115, are time-consuming, which is why the majority of published studies 
use an endogenous reference gene.  
 
Since the expression of the gene of interest is divided by the expression of the 
reference gene, the choice of reference gene is very important and will affect the 
results. The aim of Paper I was to select stably expressed genes in human adipose 
tissue using microarray data and to evaluate these genes using real-time PCR and 
compare them to established reference genes. However, as discussed by 
Vandesompele et al.116, the evaluation of an optimal reference gene based on the 
real-time PCR data becomes a circular problem because of the lack of an 
absolute reference point. Hence, Vandesompele et al developed a strategy to 
identify the most stably expressed genes by comparing the expression of all 
genes and then exclude the least stably expressed gene in a stepwise fashion. In 
this study, we extended the method developed by Vandesompele et al. by 
applying a bootstrap procedure, which enabled us to differentiate the expression 
stability of the two highest ranked genes. In addition, this extended method also 
gave us a certainty of the ranking. In this study, low density lipoprotein-related 
receptor 10 (LRP10) was found to be the most stably expressed gene. Our data 
indicate that LRP10 is a more suitable reference gene for gene expression studies 
of human adipose tissue compared to the established reference genes beta-actin, 
18S ribosomal RNA, and glyceraldehyde-3-phosphate dehydrogenase.  
 
Searching for genes predominantly expressed in 
human omental adipocytes 
Adipose tissue, especially omental (intra-abdominal) adipose tissue, is tightly 
linked to components of the metabolic syndrome117. Due to the specialized 
function of adipose tissue, it can be assumed that adipocytes express a specific 
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set of genes that other cells types do not express or only express at low levels. 
Identification of genes predominantly expressed in adipocytes could give us new 
insights into adipocyte function and may thereby provide important information 
about genes involved in the development of obesity and obesity-associated 
metabolic disease. In Paper II, genes predominantly expressed in omental 
adipocytes were therefore identified. In this search, two criteria were used: 1) the 
genes should have an expression level of 10 standard deviations higher than the 
mean of all the other tissues, and 2) the genes should have at least a 3-fold higher 
expression level than the tissue with the second highest expression (Figure 6). 
These two criteria allowed us to identify genes that have an expression level that 
is clearly separated from both the average expression level of all the tissues, but 
also from any other highly expressing tissue or cell type118. Using this approach, 
we identified 28 genes predominantly expressed in omental adipocytes. Several 
of these genes were expected including adiponectin59,119-121, aquaporin 7122, 
peroxisome proliferative activated receptor γ70, and adipsin123. However, the 
finding that acute-phase SAA (A-SAA) was predominantly expressed in 
adipocytes during nonacute-phase was unexpected. Previous published studies 
report the highest expression of A-SAA in the liver124,125. 
 
igure 6. Selection criteria for genes predominantly expressed in human omental adipocytes. 
amyloid A (SAA) genes are present in humans: SAA1, 
protein levels, which makes it difficult to distinguish between the two isoforms. 
 
F
A-U illustrates expression in other tissue or cell types. 
 
Serum Amyloid A  
Three functional serum 
SAA2 and SAA4. The SAA1 and SAA2 are referred to as “acute-phase SAA” 
(A-SAA) and these genes display a very high homology at both the RNA and 
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SAA4 is constitutively expressed and referred to as a “housekeeping” gene125. 
The third member, SAA3, has previously been detected in mouse adipose 
tissue126,127. However, most studies refer to human SAA3 as a pseudogene128. In 
addition, we were not able to detect SAA3 in human adipose tissue, adipocytes, 
or liver using RT-PCR or real-time PCR, suggesting that this gene is not 
expressed in these tissues.  
 
In similarity to CRP, SAA increases up to 1000-fold in the circulation within 1-2 
ays in response to inflammation129. Modestly increased levels of acute-phase 
studies have focused on SAA as a marker of inflammation, results 
uggest that SAA has several atherogenic effects. As described above, 
d
proteins, including SAA and CRP, are independent risk factors for coronary 
artery disease in both men and women20-22. Serum levels of SAA and CRP are 
highly correlated130 and both SAA and CRP mRNA expression are induced by 
interleukin-1β (IL-1β) in synergy with IL-6 in hepatoma cells131-133. In addition to 
effects on the transcription, data suggest that the induction of SAA mRNA by 
these cytokines involve a posttranscriptional mechanism such as increased 
mRNA stability133. SAA mRNA expression has also been found to be induced by 
oxidized LDL in monocytes/macrophages134. Multiple functions for SAA during 
inflammation have been suggested including acting as a chemoattractant for 
inflammatory cells such as monocytes, granulocytes and T-lymphocytes135,136. In 
addition, in vitro and in vivo studies indicate that SAA can induce the expression 
of proteinases, which may degrade extracellular matrix and be important in host 
defence137-139.  
 
Although most 
s
inflammatory cells are present in atherosclerotic plaques. Studies have shown 
that SAA is expressed in the plaque140 and may function as a chemoattractant 
leading to accumulation of inflammatory cells in the vascular wall. In addition, 
the ability of SAA to induce expression of extracellular matrix-degrading 
proteinases may contribute to instability of atherosclerotic plaque141. There are 
also indications that SAA influences HDL function. In mice, approximately 90% 
of SAA in plasma is found in the HDL fraction142. SAA is associated with HDL 
also in humans143. The role of SAA in HDL-metabolism is unknown but it has 
been suggested that SAA replaces apoA-I in the HDL-particle and thereby 
diminish the atheroprotective properties of HDL144. Since apoA-I containing 
HDL particles appear to contain the majority of LCAT145, it is possible that 
increased SAA may inhibit the LCAT-mediated esterification of cholesterol. It 
has also been speculated that increased levels of SAA are responsible for the 
decreased HDL levels seen during the acute-phase response and that SAA 
decrease the ability of HDL to protect LDL from oxidation.146. However, in 
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transgenic mice overexpressing SAA no decrease in HDL-cholesterol or 
replacement of apoA-I in HDL was observed147.  
 
Another possible atherogenic function of SAA is the ability of SAA to bind 
 Paper II, we demonstrate that adipose tissue is a major site of A-SAA 
revious studies indicate that adipose tissue is an important source of 
proteoglycans, which may favour the retention of HDL in the vascular wall148,149. 
From studies in rodents, it has been proposed that SAA is a ligand of the cell 
surface receptor Tanis150. Tanis has been suggested to be a link between diabetes, 
inflammatory response, and cardiovascular disease, because it is regulated by 
glucose and the expression is altered in a animal model for type 2 diabetes150. 
The rodent receptor Tanis displays homology with the human protein AD-015150 
also known as selenoprotein S.  
 
In
production during nonacute-phase. Because adipocytes can make a large 
contribution to total body weight, particularly in obese individuals, it is possible 
that the adipose tissue contributes substantially to the SAA levels in the blood. 
This is supported by the strong correlation between SAA serum levels and BMI. 
Interestingly, we found that SAA expression in adipose tissue and serum levels 
of SAA were regulated in response to diet-induced weight loss. This may be of 
importance because of the potential role of SAA in atherosclerosis. It is possible 
that SAA produced and secreted from the adipose tissue influences HDL 
properties (Figure 7). It may also function as a chemoattractant for inflammatory 
cells, which could lead to accumulation of these cells in adipose tissue. In 
addition, SAA from adipocytes could potentially affect the progression of 
atherosclerotic lesions by increased accumulation of inflammatory cells and 
degradation of the extracellular matrix. However, the role of adipose tissue-
derived SAA in the pathogenesis of atherosclerosis needs to be further 
elucidated.  
 
P
proinflammatory cytokines. Taken together, this suggests that adipose tissue may 
contribute to the low-grade systemic inflammation seen in obesity. Since SAA 
has been suggested to have multiple atherogenic effects, the production of SAA 
in adipose tissue may be a link between obesity and atherosclerosis. 
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Figure 7. Possible atherogenic effects of SAA. SAA produced and secreted from the adipocytes 
may influence HDL properties and LCAT. It may also function as a chemoattractant for 
inflammatory cells into the adipose tissue. In the circulation, SAA is associated with HDL. 
However, it is possible that SAA could dissociate from HDL and could then potentially also modify 
the progression of atherosclerotic lesion. 
 
Identification of potential susceptibility genes for 
obesity-associated metabolic disease 
It has been suggested that genetic variants involved in the development of 
complex disorders often are located in regulatory regions of the genome affecting 
the transcription rate of susceptibility genes. Polymorphisms affecting gene 
expression are common in humans151, and about 6% of all genes are estimated to 
have functional regulatory variants152. This suggests that susceptibility genes can 
be identified based on altered gene expression. However, a simple comparison of 
gene expression in individuals with disease and controls will identify all genes 
with altered expression. Thus, the genes with altered expression contributing to 
disease development can not be separated from the genes with altered expression 
as an effect of the disease itself. In the VLCD-1 study, when we compared gene 
expression in adipose tissue from obese women with and without the metabolic 
syndrome we identified 34 genes with reduced and 36 genes with increased 
expression in subjects with the metabolic syndrome compared to controls. 
Consequently, these differentially expressed genes may include susceptibility 
genes carrying sequence variations in regulatory regions responsible for the 
altered expression and potentially contributing to the disease. However, these 
genes may also include genes with altered expression by the disease itself e.g. 
regulated by insulin. In the VLCD-1 study, the insulin-regulated gene 
phosphoenolpyruvate carboxykinase 1 (PEPCK) was among the regulated genes 
at baseline. Insulin inhibits PEPCK transcription153  and as expected, we found 
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that the expression of this gene was reduced in the subjects with the metabolic 
syndrome i.e. subjects with the highest insulin levels. To exclude genes that 
differ in expression between affected and healthy subjects as a consequence of 
the disease, we analyzed gene expression in samples before and after treatment 
that ameliorates the disease phenotype. Since weight loss results in marked 
improvement of several components of the metabolic syndrome, including 
insulin resistance, hypertension, and lipid disturbances154-157, subjects were 
treated with a very low calorie diet (VLCD; 450 kcal/day) for 16 weeks followed 
by 2 weeks of gradual reintroduction of ordinary food. Gene expression was 
analyzed before, during and after this treatment. An altered expression of a gene 
even after amelioration of the disease phenotype could reveal causal 
polymorphisms either in its regulatory regions or in transcription factors 
controlling its expression. These dysregulated genes may interact with other 
genetic and environmental determinants during development of disease. During 
healthy conditions, i.e. when individuals are lean, consume a healthy diet, and 
exercise, it is likely that the altered expression of these genes do not cause a 
disease phenotype. However, in physically inactive obese individuals, consuming 
a diet rich in fat and sugar, the dysregulation of these genes may be implicated in 
disease development.  
 
Analysis of gene expression during the diet-treatment also gives us the advantage 
that the subjects then consumed the same nutrients. Several genes are regulated 
by the diet. For example, in rodents, dietary fatty acids has been found to regulate 
adipose tissue expression of multiple genes involved in lipid and glucose 
metabolism including CCAAT/enhancer binding protein alpha (C/EBPα), 
lipoprotein lipase, fatty acid synthase, hormone sensitive lipase, PEPCK, leptin, 
adipsin, PPARα, glucose transporter 4, fatty acid-binding protein, and thyroid 
hormone-responsive SPOT14158. Susceptibility genes with altered expression in 
affected individuals compared to controls are presumably easier to identify when 
diet-differences among subjects are diminished. Using this approach, S100 
calcium binding protein A1, Zn-alpha2-glycoprotein and C/EBPα were identified 
as potential susceptibility genes due to reduced expression in adipose tissue from 
obese subjects with the metabolic syndrome compared to obese controls and 
therefore selected for further studies. 
 
S100 calcium binding protein A1 
In Paper III, S100 calcium binding protein A1 (S100A1) was identified as a 
potential susceptibility genes for metabolic disease. S100 proteins are 
characterized by two Ca2+-binding EF-hands (helixloophelix motif), located in 
the N- and C-terminal part of the protein, respectively. The two EF-hands are 
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connected through a region referred to as the hinge region. Several S100 proteins 
have been identified and differ from one another mainly in the hinge region and 
in the extended C-terminal part of the proteins159. Most S100 proteins forms 
homodimers and in some cases heterodimers. S100A1, a 21 kDa protein, is 
highly expressed in heart and skeletal muscle where it has been shown to be a 
regulator of muscle contractility. Previous results shows that S100A1 improves 
the contractile performance by both regulating sarcoplasmic reticulum calcium 
ion handling and myofibrillar calcium ion responsiveness160. S100A1 binds 
multiple proteins in the sarcomere including titin161, actin-capping protein Cap-
Z162, nebulin163 and the kinase domain of the titin-related protein twitchin164. 
S100A1 interacted with the kinase titin in a Ca2+-dependent manner and thereby 
decrease the interaction between titin and filamentous F-actin161. It was proposed 
that Ca2+/S100A1 reduce the titin-based inhibition of F-actin motility. 
Furthermore, S100A1 has been shown to bind to the Ca2+-releasing channel SR-
ryanodine receptor located in the sarcoplasmatic reticulum165 and increase the 
Ca2+ 2+-induced Ca  release166,167. In accordance with these findings, S100A1-
deficient mice have normal cardiac function under baseline conditions but have 
significantly reduced contraction rate and relaxation rate responses to ß-
adrenergic stimulation, associated with a reduced Ca2+ 168 sensitivity . S100A1 has 
also been shown to affect several glycolytic enzymes including fructose-1,6-
bisphosphate aldolase169, phosphoglucomutase170 and glycogen phosphorylase 
A171. 
 
In the Quebec Family Study (QFS), evidence for linkage to resting metabolic rate 
(RMR) was observed on chromosome 1q21.1 – q21.2 in close proximity to the 
S100A1 locus107. The RMR quantitative trait locus also co-localized with 
genomic regions previously linked to components of the metabolic syndrome172-
174. Moreover, a strong positive correlation between RMR and the metabolic 
syndrome was observed in the QFS. We found that S100A1 genotype was 
associated with resting metabolic rate in QFS in subjects from families 
contributing to the linkage to RMR at 1q21. Thus, our data suggest that S100A1 
influence resting energy expenditure and that the expression of S100A1 is 
dysregulation in obese subjects with the metabolic syndrome compared with 
controls. The role of S100A1 in adipose tissue is not clear. However, it is 
possible that S100A1 is a calcium sensor also in this tissue, which is interesting 
since it has been suggested that intracellular Ca2+ levels could play a role in the 
regulation of adiposity175. It is possible that S100A1 could in part account for the 
observed correlation between metabolic syndrome and energy metabolism. 
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Zn-alpha2-glycoprotein 
In Paper IV, Zn-alpha2-glycoprotein (ZAG) was identified as a potential 
susceptibility gene for metabolic disease. The expression of ZAG was reduced in 
adipose tissue from obese subjects with the metabolic syndrome compared with 
obese controls. ZAG has previously been identified as an adipokine, produced 
and secreted from adipocytes176,177. However, in our study ZAG expression in the 
adipose tissue was low compared with the expression in liver and prostate 
(unpublished data). Nevertheless, ZAG may have a local effect in adipose tissue. 
Interestingly, overexpression of ZAG in 3T3-L1 adipocytes has been reported to 
lead to an increase in adiponectin mRNA levels178. Moreover, we observed a 
strong correlation between ZAG mRNA levels in adipose tissue and serum 
adiponectin levels (Figure 8; unpublished data). 
 
 
Figure 8. Correlation between adipose tissue ZAG mRNA levels and serum levels of 
adiponectin during diet induced weight loss in the VLCD-2 study.  
 
The human ZAG gene spans approximately 9 kilobases, has four exons, and 
encodes a 41-kDa secretory protein. When sequencing the conserved regions of 
the ZAG gene, we identified 9 SNPs. Only one of these SNPs was previously not 
reported. Uria et al isolated two previously unknown isoforms of ZAG from rat 
liver, with 123 and 138 nucleotides inserted in the RNA between exon two and 
three, which resulted in a 41 and 46 amino acids insert in the protein, 
respectively179. However, we were not able to detect any ZAG isoforms in human 
liver or adipose tissue (unpublished data).  
 
ZAG is a major histocompatibility complex (MHC) class I homolog180,181, 
produced in the liver, prostate, kidney, salivary glands, mammary glands, and 
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sweat glands182. ZAG was first isolated from plasma and has later been found in 
other body fluids such as urine, saliva and sperm. In similarity to MHC class I, 
ZAG has a binding pocket. However, in contrast to MHC class I, which binds 
peptides in its pocket, ZAG is thought to bind a hydrophobic molecule. Binding-
studies have shown that ZAG has high affinity for unsaturated fatty acids 
including eicosapentaenoic acid and docosahexaenoic acid183. In similarity to 
other MHC class I proteins, it is likely that the binding of different ligands affects 
ZAG’s function and it’s interaction with a putative receptor on target cells. 
Previously, ZAG has mostly been studied in cancer cachexia, the wasting 
syndrome causing depletion of adipose and muscle tissue. A tumour-secreted 
lipid-mobilizing factor (LMF) was identified and later found to be identical to 
ZAG184,185. When given to rodents, ZAG stimulates lipolysis in adipose tissue 
resulting in a release of free fatty acids and glycerol186. The animals consumed 
the same amount of food, but decreased their weight as a result of increased 
lipolysis and energy expenditure186. When body composition was analyzed, it 
was discovered that the animals reduced their weight solely by decreasing the 
adipose tissue mass. In rodents, ZAG’s effect on lipolysis in adipose tissue is 
thought to be mediated by binding to the β3-adrenergic receptor187.  
 
Our study showed a relationship between ZAG and cholesterol metabolism. 
Serum levels of ZAG were positively correlated with serum levels of total 
cholesterol in humans. In agreement with these results, the ZAG rs4215 CC 
genotype was associated with reduced ZAG gene expression, reduced serum 
levels of ZAG and low serum total cholesterol levels in humans. ZAG-deficiency 
in mice resulted in reduced hepatic cholesterol content and decreased hepatic 
expression of HMG-CoA reductase but normal serum cholesterol levels. This is 
compatible with an increased retention time of cholesterol in plasma, indicating a 
decreased cholesterol turnover. Unexpectedly, we also observed that the ZAG 
rs4215 CC-genotype was associated with increased risk of coronary heart 
disease. This genotype was associated with lower serum levels of total 
cholesterol, but also lower levels of HDL-C. In addition, it is possible that the 
lower expression of ZAG in adipose tissue, associated with this genotype, can 
result in reduced serum adiponectin levels. In fact, individuals with the rs4215 
CC-genotype have lower serum adiponectin levels compared with non-CC in the 
VLCD-2 study (CC 9.5 ± 5.4 μg/mL, non-CC 12.8 ± 7.1 μg/mL, p=0.05; 
unpublished data). 
 
Recently, ZAG deficient mice were found to have reduced lipolysis in adipose 
tissue and increased body weight188. However, we did not observe a difference in 
body weight between ZAG-deficient mice (ZAG-/-/apoB100+/-) and their 
littermate controls (ZAG+/+/apoB100+/-). There were several differences between 
 39
Molecular mechanisms in obesity-associated metabolic disease 
___________________________________________________________________________________________________________________________________________________________________________________ 
these two studies that may explain the divergence including time of follow up, 
diet, number of generations backcrossed, and the use of an apoB100 transgenic 
background. 
 
The function of ZAG has to be further elucidated. However, this and previous 
studies indicate that ZAG could play an important role in lipid metabolism i.e. 
potentially be involved in the regulation of both lipolysis and cholesterol 
synthesis (Figure 9). Interestingly, ZAG may also affect expression and serum 
levels of adiponectin. 
Adipose 
tissue 
ZAG 
glycerol 
NEFA 
ZAG 
Cholesterol 
synthesis 
adiponectin 
Liver lipolysis 
 
Figure 9. Possible effects of ZAG. Previous studies have shown that ZAG stimulates lipolysis in 
adipose tissue, which increases the release of NEFA and glycerol. In addition, ZAG may have a 
local role in adipose tissue, where it potentially stimulates adiponectin expression and secretion. 
Our data indicates that ZAG can affect cholesterol synthesis. 
 
CCAAT/enhancer binding protein alpha 
CCAAT/enhancer binding proteins (C/EBP) are members of the basic-leucine 
zipper class of transcription factors and acts as homo- or heterodimers189. Six 
members have been identified and four of these are expressed in adipose tissue: 
C/EBPα, C/EBPβ, C/EBPδ and C/EBPζ189. Two isoforms of C/EBPα are formed 
from the same mRNA by a ribosomal scanning mechanism190,191. The full-length 
protein is 42 kDa. A fraction of the ribosomes ignore the first two AUG codons 
and initiate translation at the third AUG, 351 nucleotides downstream of the first 
AUG, generating a 30-kDa protein190,191. This shorter protein has an altered 
transactivation potential compared with the 42-kDa isoform190,191.  
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C/EBPα was identified as a potential susceptibility gene for metabolic disease in 
Paper V. Its expression in adipose tissue was correlated to serum glucose levels 2 
hours after an oral glucose tolerance test. In addition, C/EBPα expression was 
lower in adipose tissue from obese subjects with the metabolic syndrome 
compared with controls during treatment with a very low calorie diet. The inter-
individual variation in C/EBPα expression decreased during diet compared to 
baseline. It is possible that the larger inter-individual variation at baseline is a 
result of dietary effects on C/EBPα expression since C/EBPα is known to be 
regulated by dietary fatty acids158. This may explain why we (at baseline in 
VLCD-2) and others192-194 do not observe significant differences in C/EBPα 
expression between individuals with insulin resistance/metabolic syndrome and 
controls.  
 
C/EBPα-deficient mice die because of hypoglycemia within 8 hours after 
birth  demonstrating that 195,196 C/EBPα has an important role in glucose 
metabolism. In these mice, expression of enzymes in the glycogen synthesis and 
gluconeogenesis were altered, which is likely to cause the hypoglycemia 
observed in these mice. Furthermore, adipocytes from these mice fail to 
accumulate lipids leading to diminished adipose tissue. In contrast to whole body 
C/EBPα-null mice, mice lacking hepatic C/EBPα have normal blood glucose 
levels and glycogen synthesis but are glucose intolerant and develop 
hepatosteatosis197. We found that C/EBPα regulates the glycogen synthase 1 
promoter, which may be important for glycogen synthesis in adipose tissue. 
Furthermore, we found that insulin induces C/EBPα expression in human 
adipocytes. However, subjects with the metabolic syndrome i.e. with higher 
insulin concentration, have lower expression of C/EBPα in subcutaneous adipose 
tissue compared with controls in the VLCD-2 study. It is possible that individuals 
with insulin resistance, i.e. individuals in which insulin fails to evoke a normal 
response, can not up-regulate C/EBPα expression in response to insulin.  
 
C/EBPα is a key regulator of adipogenesis198 and promotes differentiation 
through binding of cdk2 and cdk4 which prevents them from binding cyclins 
leading to growth arrest199. Deletion of specific transactivation domains in 
C/EBPα leads to reduced adipogenesis in NIH3T3 fibroblasts200. In addition, 
overexpression of C/EBPα in 3T3-L1 preadipocytes induces their differentiation 
into mature adipocytes201,202 and the inhibition of C/EBPα by antisense RNA in 
these cells blocks this process203. In concordance with these results, we found that 
C/EBPα regulates multiple genes in the lipid and glucose metabolism including 
adiponectin, hexokinase 2, lipoprotein lipase, diacylglycerol O-acyltransferase 1 
and 2, CD36 antigen, ATP-binding cassette, sub-family D, member 2, acyl-CoA 
synthetase long-chain family member 1, hydroxysteroid 11-beta dehydrogenase 
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1, and glycogen synthase 1. Up-regulation of these genes may, among other 
things, result in increased hydrolysis of triglycerides in the circulation and 
increased uptake of free fatty acids, glycerol and glucose in adipocytes leading to 
increased triglyceride storage. The lower expression of C/EBPα observed in the 
subjects with the metabolic syndrome i.e. individuals with insulin resistance may 
contribute to the higher serum levels of TG and glucose found in these subjects 
(Figure 10).  
Adipose tissue 
 
Liver 
C/EBPα 
Glucose uptake 
TG accumulation 
Liver steatosis 
DGAT2 DGAT1
LPL HK2 GYS1 
ADIPOQ  
s-TG 
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Figure 10. Possible effects of low C/EBPα expression in adipose tissue. Lower expression of 
CEBPα in adipose tissue from subjects with the metabolic syndrome compared to controls may 
lead to higher serum levels of triglycerides and glucose. C/EBPα, CCAAT/enhancer binding 
protein α; ADIPOQ, adiponectin; DGAT, diacylglycerol o-acyltransferase; LPL, lipoprotein lipase; 
HK, hexokinase, GYS, glycogen synthase; s-glucose, serum levels of glucose; s-TG, serum levels 
of triglycerides. 
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CONCLUDING REMARKS AND FUTURE 
PERSPECTIVE 
The overall aim of this thesis was to identify susceptibility genes important in the 
development of obesity-associated metabolic disease and to increase our 
understanding regarding the function of these genes. Two different expression-
based strategies were applied in order to achieve this aim. Using the first 
approach, genes predominantly expressed in adipocytes were identified. In this 
study (Paper II), adipose tissue was found to be a major production site of SAA 
during nonacute-phase. Since it has been suggested that SAA have multiple 
atherogenic effects, it is possible that SAA from adipose tissue is a link between 
obesity and atherosclerosis.  
 
Using the other approach, potential susceptibility genes for metabolic disease 
were identified based on altered expression in affected individuals compared to 
controls using DNA microarray. However, a simple comparison of gene 
expression in affected individuals compared with controls will identify all genes 
with altered expression. Thus, the genes with altered expression contributing to 
disease development can not be separated from the genes with altered expression 
as an effect of the disease itself. We therefore also investigated the gene 
expression in affected subjects and controls after amelioration of the disease 
phenotype. We found that this strategy reduce the number of genes with altered 
expression. In Papers III-V, S100A1, ZAG and C/EBPα were identified as 
potential susceptibility genes using this approach. In subsequent studies of 
humans and mice, these genes were linked to components of the metabolic 
syndrome or metabolic parameters associated with metabolic disease. Thus, our 
findings suggest that all three genes identified by this strategy are promising 
candidate genes for metabolic disease. We have applied this approach for 
identification of potential susceptibility genes for metabolic disease. However, 
the same strategy could also be used for other diseases.  
 
To increase our knowledge regarding the role of these genes in the pathology of 
metabolic disease, functional studies are required including knock out mice and 
mice overexpressing the gene of interest. In Paper IV, the role of ZAG in 
cholesterol metabolism was investigated in ZAG-deficient mice. Future studies 
of ZAG will include a more thorough characterization of these mice during 
different conditions, such as starvation. Effects of different diets will be 
investigated. In addition, adenovirus for studies of ZAG overexpression in vivo 
has been generated. In addition to wild type ZAG, adenoviruses carrying the 
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ZAG cDNA with mutations in the sequence coding for the binding pocket have 
been generated to study the effects of the ligand-binding pocket. One of these 
mutations is thought to increase affinity for the ligand, while the other mutation 
is likely to decreases the affinity204. Taken together, this mouse model and these 
tools can help us to clarify the role of ZAG in metabolic disease. Functional 
studies will also be required to further elucidate the role of SAA, S100A1 and 
C/EBPα in the pathogenesis of metabolic disease. 
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